conventional antipsychotics atypical antipsychotics cerebrovascular accident ischemic stroke transient ischemic attack hemorrhagic stroke stroke dementia a b s t r a c t Background: Studies investigating the association between antipsychotic use and the risk of cerebrovascular accident (CVA) showed inconsistent results. Aim: Conduct a systematic review and meta-analysis to evaluate whether use of antipsychotics is associated with increased risk of CVA. Methods: Major electronic databases were searched from 1970 to October 2016 for observational studies investigating the risk of CVA among users of antipsychotics. Pooled estimates of odds ratios (ORs) and 95% confidence intervals (CIs) were obtained by random effects meta-analysis. Results: Of 1171 citations identified, 10 studies were considered eligible. Significant increase in risk of CVA was associated with first-generation antipsychotics (OR 1.49; 95% CI 1.24e1.77) but not with secondgeneration antipsychotics (OR 1.31; 95% CI 0.74e2.30). Use of any antipsychotics in patients with dementia was associated with a low risk of CVA (OR 1.17; 95% CI 1.08e1.26).
Use of antipsychotics among the public continues to rise around the world. 1e5 Increases in national antipsychotic utilization were seen in the United States from 1995 to 2008 and in England from 1998 to 2010. 1, 4 Throughout much of the world, the prescribing indication for antipsychotics is principally for schizophrenia, but these medications are commonly prescribed for a broad range of diseases other than schizophrenia. Such diseases include psychotic and affective disorders, personality and anxiety disorders, and agitation in dementia. 5, 6 The rise in the use of antipsychotics is alarming as several lifethreatening adverse effects have been reported with their use. Studies have linked the use of antipsychotic medications to adverse metabolic events, adverse cardiovascular events, and even death. 6e13 In addition, the use of antipsychotics has been associated with an increased risk of cerebrovascular accidents (CVAs) in a number of studies and systematic reviews; however, with conflicting evidence in the literature, this association remains controversial. 14, 15 Until recently, the positive correlation between antipsychotic use and risk of CVA was primarily seen in elderly adults, particularly those with dementia. 16e19 It is unclear whether use of antipsychotics in the general population is also associated with increased risk of cerebrovascular events. In addition, the risk of CVA reported in the literature varies considerably depending on the type of antipsychotic used. A number of studies have shown a higher risk of CVA associated with typical or first-generation antipsychotics (FGAs) compared with atypical or second-generation antipsychotics (SGAs), 6, 16, 20 others have suggesting the opposite, 21, 22 and some studies have even indicated no difference between the 2 classes. 23e25 Despite the controversy in the available evidence, the US Food and Drug Administration issued a boxed warning on the increased risk of death and cerebrovascular events when FGAs are used for the off-label indication of dementia. 26 Given the contradicting nature of the evidence, we conducted a systematic review and meta-analysis to determine whether use of antipsychotics is associated with an increased risk of CVA.
Methods

Search Strategy
We performed this study in accordance with the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines. Ethical Committee approval was not required for the meta-analysis. We searched PubMed and EMBASE for published studies from 1970 to October 2016 that explored the risk of CVA associated with use of antipsychotic medications. The search terms included "antipsychotic," "anti psychotic," "antipsychotic drugs," "Chlorpromazine," "Haloperidol," "Bromperidol," "Fluphenazine," "Zuclopenthixol," "Pentixol," "Flupentixol," "Levopromazine," "Perphenazine," "Pimozide," "Penfluridol," "Sulpiride," "Amisulpride," "Amoxapine," "Asenapine," "Aripiprazole," "Blonanserine," "Clozapine," "Iloperidone," "Melperone," "Olanzapine," "Risperidone," "Paliperidone," "Quetiapine," "Sertindole," "Lurasidone," "Ziprasidone," "cerebrovascular accidents," "cerebrovascular disorders," "ischemic stroke," "hemorrhagic stroke," "transient ischemic attack," and "stroke." Antipsychotics include FGAs and SGAs based on the US Food and Drug Administration drug classification. 27e29 We used "cerebrovascular disorders," "ischemic stroke," "transient ischemic attack," "TIA," "hemorrhagic stroke," "stroke," and "brain infarction" as the search terms for the outcomes of interests. We did not set restrictions on geography or language, and we did not seek unpublished investigations. Two investigators (W. H., C. L.) independently examined all titles and abstracts and obtained full texts of potentially relevant articles. Following the database search, a review of the abstracts was conducted to rule out the studies that involved case reports, case series, reviews, editorials, clinical trials, systematic reviews, meta-analyses, or clinical guidelines. To be eligible for inclusion, studies must have met the following criteria: (1) observational study with a control group, (2) nonuse of any antipsychotic served as a reference group, (3) reported data on CVA outcomes, and (4) offered sufficient data to construct risk estimates. The same cohort reported in different articles was evaluated to include the most recent publication. Publications by the same author or group of authors were also carefully investigated to exclude overlapping cohorts or results. The most recent study results were included for further meta-analysis. We abstracted data from full-text articles using structured review forms, and disagreements were resolved by consensus meetings.
Data Extraction and Quality Assessment
For all studies, we extracted information on the first author's surname, year of publication, country, study design, sources of database, sociodemographics, sample sizes, case numbers, duration of study, exposure, outcomes of interests, crude and adjusted effect sizes as available, and matching and confounding factors. We used the Newcastle-Ottawa Scale (NOS) to assess the quality of included studies. 30 Studies awarded more than 6 stars were considered high quality, and 9 stars represented the highest quality.
Data Synthesis
Our primary measure of interest was the pooled odds ratio (OR) of CVA related to the exposure of any antipsychotics. Secondary measures of interest were exposure to FGAs or SGAs compared with nonusers. Subgroup analyses were conducted for the following subgroups: elderly population, population with dementia, case-control study design, and population-based study design. Pooled ORs were estimated by the Mantel-Haenszel method. 31 Publication bias was assessed using the Begg adjusted rank correlation test and the Egger regression asymmetry test. The Begg adjusted rank correlation test was used to measure the correlation between estimates of treatment effect and variances. Similarly, the Egger asymmetry test is a regression of the standardized treatment effects on the standard errors. For both methods, a significant result suggests correlation between effect size and estimates of precision which would be evidence of publication bias. Visual assessment was conducted by constructing funnel plots. A funnel plot is a scatter plot of the effect measure estimate on the horizontal axis vs the standard error of the effect estimate on the vertical axis. The plot should form a pyramid in the absence of bias. 32, 33 To assess consistency and evaluate heterogeneity, we calculated the I 2 statistic. A fixed-effect model was used for I 2 less than 50%, whereas random-effects model was used for studies with I 2 greater than 50%. 34, 35 All meta-analyses were performed using Stata statistical software v 12 (StataCorp, College Station, TX).
Results
Study Selection and Characteristics
The number of articles excluded and the reasons for exclusion of each individual article are reported in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram ( Figure 1 ). Our search strategy yielded 1171 references, 23 of which were considered eligible for full-text review. Of these, we excluded 9 studies for the reasons reported in the Figure 1 . Finally, 10 articles met the inclusion criteria and were included in the meta-analysis. These 10 studies 16 databases, 16, 19 ,36e42 whereas 1 study used an electronic health record (Table 1) . 25 All studies included adult participants, 8 of which focused on elderly patients, 16, 19 ,36e39,41,42 and 5 of which included patients with dementia. 16, 19, 38, 41, 42 Characteristics of individual studies are summarized in Table 1 .
Study Quality
Quality evaluation by the NOS is summarized in Table 2 . All included studies used appropriate design. The studies varied with respect to their exposure and case definitions. Current use of FGAs or SGAs was the most frequent measure of exposure, whereas other studies further classified drug use into recent or past users, high-dose or low-dose users, and short-term or long-term users. All 10 included studies used the definition of CVA provided by the International Classification of Diseases, Ninth Revision, Clinical Modification or International Classification of Diseases, Tenth Revision, Clinical Modification as their main outcome. Only 1 study performed CVA diagnosis validation from reviewed medical records. 42 The studies also varied in the adjusted covariates. All studies comprehensively adjusted for potential confounders in their analysis. In terms of overall quality, 5 studies received 9 stars and 4 studies received 8 stars when evaluated using NOS, indicating low risk of bias (Table 2) .
Antipsychotics and Risk of CVA
Nine out of 10 studies examined the pooled use of both FGAs and SGAs (Table 3 In addition, studies were evaluated to determine whether CVA risk differs between FGAs and SGAs ( Figure 2B and C 
Publication Bias
The test for publication bias did not yield significant results in 3 main medication categories. The results of the Egger test indicated no evidence of publication bias in both FGA and SGA users (P ¼ .72), which was consistent with the Begg test (P ¼ .76). Among FGA users, no significant evidence of potential publication bias was noted using the Begg test (P ¼ .46) and Egger test (P ¼ .63). The Begg test of SGAs suggested no significant evidence of potential publication bias (P ¼ 1.00) ( Table 4) . Funnel plots of the 3 main exposure categories are shown in Figure 3 . These plots present no clear asymmetry and support the results of the aforementioned tests.
Discussion
We reviewed the literature and quantitatively summarized the existing observational studies that evaluated the association between antipsychotic use and CVA risk. A total of 186,188 antipsychotic users and roughly 17,000 CVA cases were identified, which is by far the largest systematic review conducted to date. Our meta-analysis showed that use of antipsychotics increases CVA risk, regardless of patient age or study design. Compared with nonusers, users of antipsychotic medications have an approximately 1.5-fold increased risk of developing CVA. Heterogeneity of strengths of association may reflect true pharmacologic differences in type of antipsychotics, differences in study methodology, and the distribution of effect modifiers such as patient age or presence of dementia. Greater risk was seen among the elderly population, whereas risk of CVA in dementia patients was not as pronounced. In the subgroup analysis, FGAs and SGAs showed differences in CVA risk. Use of FGAs was associated with a nearly 1.5-fold increased risk of CVA, whereas use of SGAs was associated with an attenuated (1.3-fold) and nonsignificant increase in CVA risk.
Our overall findings are consistent with the results reported in 2 previous systematic reviews, which suggest antipsychotics may trigger cerebrovascular events. 43, 44 The review by Sacchetti et al 43 included both randomized clinical trials and observational studies, Neither review, however, performed meta-analyses to provide summary estimates. The review by Sacchetti et al showed that incidence of CVA was consistently increased in the antipsychotic arm, but the small sample size of each trial prevented a conclusive outcome. The Pratt et al review was also descriptive but noted that the results may have been greatly influenced by the study design. 44 Moreover, the 2 reviews suggested a low risk of CVA associated with antipsychotic use among people with dementia, but a high CVA risk associated with antipsychotic use in the elderly population. Unlike the aforementioned reviews, our updated review computed pooled summary estimates across different subgroups, determined sources of heterogeneity, and included 5 additional eligible studies. Our quantitative analysis confirmed the observation that elderly users of antipsychotics had a moderate risk of CVA but users with dementia did not have a low risk of CVA as previously observed. All but 4 studies used case-control design so a subgroup analysis could not be performed for other study designs. Some studies used hospital patients as their control, which could attenuate the risk of CVA. The large number of antipsychotic users is a main strength of this study, allowing for analysis of CVA risk differences between FGA users and SGA users. Users of FGAs were found to have a 1.5-fold greater risk of CVA when compared with nonusers. In contrast to findings of previous meta-analyses, this study shows a nonsignificant association between use of SGAs and risk of CVA (OR 1.31; 95% CI 0.74e2.30; I 2 ¼ 94.8%). It should be noted that the CI is wide and the measure for statistical heterogeneity (I 2 ) is high. Two of the eligible studies reported an increased CVA risk among SGA users, 39,41 whereas 4 studies reported no increased risk. 16, 37, 38, 42 The heterogeneity in the observed risk of CVA can be partly attributed to differences in study design. For study design, 5 studies were case-control, 16, 19 ,36e38 1 casecase-time-control study, 40 1 self-control case series study, 41 1 crosssectional study, 25 and 2 cohort studies. 39, 42 Heterogeneity in CVA risk may also be attributed to differences in patient selection as demonstrated in Table 1 SGAs, more high quality population-based observational studies are required that employ appropriate study designs. A few meta-analyses have examined the association between antipsychotics and cerebrovascular events in the population with dementia. However, the prevalence of dementia is rather low in the general population, ranging from 38 to 421 per 100,000 persons. 45 Given the low prevalence of dementia, it is important to determine whether the risk of CVA differs among general users of antipsychotics compared with the population with dementia. To the best of our knowledge, this is the first meta-analysis to investigate the association between use of any antipsychotics and the risk of CVA in populationbased studies. Our results suggest a high risk of CVA (51%) in general users of antipsychotics and a low risk of CVA (17%) in dementia patients.
Although we have performed a very thorough literature review and meta-analysis, our research is not without limitations. First, included studies were heterogeneous in terms of study design, timing of antipsychotic exposure, and diagnostic outcomes. In addition, despite the fact that the majority of studies were adjusted for many confounders with high quality results of NOS assessment, we cannot exclude the possibility of residual confounding for observational studies, especially being that the effect estimates differed greatly between a self-control case series design and traditional case control or cohort designs. Finally, this meta-analysis was limited in its ability to substantiate potential mechanisms linking antipsychotic use and risk of CVA, such as direct vascular toxicity, coagulation dysfunction, or weight gain.
To conclude, our study suggests that overall antipsychotic exposure is associated with an increased risk of CVA. In addition, subgroup analysis suggests that elderly patients have a higher risk of CVA than the population with dementia. Antipsychotic treatments should still be prescribed based on elderly patients' individual benefits and risks especially for behavioral and psychological symptoms of dementia. These associations may be causal but the possibility of residual confounding cannot be excluded. It is unlikely that more detailed information on a large population of antipsychotic users will become available in the immediate future. Clinicians should be aware of the higher risk of CVA among patients using antipsychotics, particularly in FGA users and the elderly population.
